D
Monte Rosa Therapeutics, Inc. GLUE
$12.31 $0.312.58% NASDAQ
Recommendation
Prev Close
$12.85
Volume
2,255
Avg Vol (90D)
1,074,095
Market Cap
$793.61M
Dividend & Yield
--
52-Week Range
$3.50 - $13.22
P/E (TTM)
43.90
EPS (TTM)
$0.29
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Monte Rosa Therapeutics Inc (GLUE) Q3 2025 Earnings: EPS Misses Estimates, Revenue Surges to ...
11/6/2025 - GuruFocus
Monte Rosa Therapeutics sees cash runway through 2028
11/6/2025 - The Fly
Monte Rosa Therapeutics reports Q3 revenue $12.8M, consensus $7.37M
11/6/2025 - The Fly
Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates
11/6/2025 - GuruFocus
Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates
11/6/2025 - Globe Newswire
Monte Rosa Therapeutics (GLUE, $12.31) Moving Average Convergence Divergence (MACD) Histogram turned negative on November 5, 2025
11/6/2025 - Tickeron - Stocks
Monte Rosa Therapeutics (GLUE, $12.31) Aroon Indicator entered an Uptrend on November 05, 2025.
11/6/2025 - Tickeron - Stocks
Monte Rosa Therapeutics (GLUE, $12) Aroon Indicator entered an Uptrend on November 04, 2025.
11/5/2025 - Tickeron - Stocks
Mirum Pharmaceuticals, Inc. (MIRM) Surpasses Q3 Earnings and Revenue Estimates
11/4/2025 - Zacks Investment Research
Monte Rosa Therapeutics (GLUE, $12.07) Aroon Indicator entered an Uptrend on November 03, 2025.
11/4/2025 - Tickeron - Stocks
Monte Rosa Therapeutics (GLUE, $12.07) RSI Indicator left the overbought zone on November 03, 2025
11/4/2025 - Tickeron - Stocks
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
11/3/2025 - GuruFocus
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
11/3/2025 - Globe Newswire
Monte Rosa Therapeutics (NASDAQ:GLUE) Given Sell (D+) Rating at Weiss Ratings
11/1/2025 - MarketBeat
Monte Rosa Therapeutics (GLUE, $12.85) Aroon Indicator entered an Uptrend on October 31, 2025.
11/1/2025 - Tickeron - Stocks
Monte Rosa Therapeutics (GLUE, $13.01) Aroon Indicator entered an Uptrend on October 30, 2025.
10/31/2025 - Tickeron - Stocks
Monte Rosa Therapeutics (GLUE, $12.5) Aroon Indicator entered an Uptrend on October 29, 2025.
10/30/2025 - Tickeron - Stocks
Monte Rosa Therapeutics (GLUE, $12.43) Aroon Indicator entered an Uptrend on October 28, 2025.
10/29/2025 - Tickeron - Stocks
Monte Rosa Therapeutics (NASDAQ:GLUE) Reaches New 1-Year High - Still a Buy?
10/28/2025 - MarketBeat
Novartis Lags Q3 Earnings, Announces $12B Avidity Biosciences Acquisition
10/28/2025 - Zacks Investment Research
Monte Rosa Therapeutics (GLUE, $12.32) Aroon Indicator entered an Uptrend on October 27, 2025.
10/28/2025 - Tickeron - Stocks
Monte Rosa Therapeutics (GLUE, $11.14) Moving Average Convergence Divergence (MACD) Histogram turned positive on October 24, 2025
10/25/2025 - Tickeron - Stocks
Monte Rosa Therapeutics (GLUE, $11.14) RSI Indicator left the overbought zone on October 24, 2025
10/25/2025 - Tickeron - Stocks
Monte Rosa Therapeutics (GLUE, $11.14) Aroon Indicator entered an Uptrend on October 24, 2025.
10/25/2025 - Tickeron - Stocks
Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Up 11.7% - Should You Buy?
10/24/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
$177.99M
EBITDA (TTM)
$23.30M
EBIT (TTM)
$14.96M
Net Income (TTM)
$24.17M
Balance Sheet
Total Assets (Q)
$359.59M
Total Debt (Q)
$41.13M
Total Liabilities (Q)
$91.51M
Book Value Per Share (Q)
$4.34
Cash Flow
Cash from Operations (TTM)
$27.72M
Cash from Investing (TTM)
-$68.05M
Cash from Financing (TTM)
$1.00M
Net Change in Cash (TTM)
-$39.33M
Filings
Filing Date
Thursday, August 7, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 3 and 7 (est)
Price History
Loading...
Beta
1.66
7-Day Total Return
18.59%
30-Day Total Return
88.51%
60-Day Total Return
181.05%
90-Day Total Return
164.16%
Year to Date Total Return
73.14%
1-Year Total Return
38.31%
2-Year Total Return
259.94%
3-Year Total Return
36.32%
5-Year Total Return
--
52-week Low
Apr 07, 2025 - $3.50
52-week High
Oct 31, 2025 - $13.22
Valuation
Market Cap
$793.61M - Small Cap
Enterprise Value
$544.14M
Price/Sales (TTM)
5.93
Price/Book (Q)
2.96
Dividends and Shares
Shares Outstanding
82.19
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.monterosatx.com
Phone Number
617 949 2643
Address
321 Harrison Avenue
Boston, MA 02118
Country
United States
Year Founded
2019
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to... more
NASDAQ 11/05/2025 4:00PM Eastern Quotes delayed